The use of genetically engineered mice has grown exponentially. Transgenic deficient mice are now widely used to study: the process of malignant transformation, tumor suppressor genes, chemoprevention, carcinogenesis and organ-specific cancers. In fact, the genetic manipulation of mice is used in virtually every field of biomedical investigation. It is arguably the most potent tool available to dissect gene function in physiology and pathophysiology. However, because of the prohibitive costs and the technical sophistication required to establish these procedures within individual laboratories, it is essential to support these technologies as a shared resource. This requires an efficient and cost-effective common facility that enables individual investigators to have both transgenic mice expressing genes of interest and mice carrying gene disruptions created for them. The techniques available from this Resource place these potent tools for analysis in the hands of all of our investigators. When used in combination with the other modern techniques supplied by the Center's Histology and Molecular Pathology facilities, it gives our investigators unlimited opportunities to examine pathogenetic processes from several perspectives simultaneously. Our current facility has an established track record of enabling the creation of both transgenic mice and knockout mouse strains for multiple Cancer Center laboratories. Without such a centralized resource, most laboratories would not be in a position to utilize these pow4erful models, severely limiting the research and granting opportunities for our biomedical and cancer research community, severely limiting the research and granting opportunities for our biomedical and cancer research community. The Transgenic Mouse Shared Resource of UCSD Cancer Center is widely respected in the community and regarded as an essential resource for modern cancer research. It substantially improves the quality, quantity and creativity of the research, while also enhancing cost-effectiveness and efficiency.
| Dow, Michelle; Pyke, Rachel M; Tsui, Brian Y et al. (2018) Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115:E9879-E9888 |
| Que, Xuchu; Hung, Ming-Yow; Yeang, Calvin et al. (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301-306 |
| Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135 |
| Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42 |
| Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593 |
| Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69 |
| Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089 |
| Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809 |
| Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev : |
| Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36 |
Showing the most recent 10 out of 862 publications
